Bayer May Sell More Businesses Amid Monsanto Deal Delays

The transcript covers Bayer's strategic plans amid the Monsanto acquisition, including divestitures and post-acquisition priorities. It highlights the company's record growth in pharmaceuticals, challenges in consumer health, and financial strategies. The discussion also touches on drug pricing in the US and Bayer's approach to innovation. Finally, it addresses the strategic alignment of Bayer's agriculture and health sectors.

What is Mr. Bowman's perspective on the pricing of pharmaceutical products in America?

What does Mr. Bowman believe is necessary for the American people regarding pharmaceutical products?

What is the company's strategy regarding the combination of agriculture and health sectors?